Regulatory
FDA Grants Breakthrough Status to Lilly’s Olomorasib in KRAS-Mutant Pancreatic Cancer
The KRAS G12C inhibitor earned the designation for previously treated advanced pancreatic cancer, one of oncology’s hardest targets, based on early-phase trial data.